newsfilter
← Latest News
GlobeNewswire·

iTeos Provides Business Updates and Clinical Development Plans for 2023

- 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - Eleven clinical trials planned or ongoing against multiple tumor